Can CBD Treat SARS-CoV-2 Variants? Patent Filings Say Yes

Patent Forecast has highlighted in two insights (Can CBD Obliterate COVID Variants? Hello Nasal Spray & Were You Exposed to COVID-19? Here’s What You Could Do Next.) the increase in filings for treating COVID-19 with cannabinoids, specifically pure cannabidiol (CBD). While research has been inconclusive, laboratory tests have shown in vitro and in mice that CBD could be effective in preventing replication of SARS-CoV-2 in cells. This has commenced clinical trials and increased patent filings in the space especially as new variants circulate and test the efficacy of the COVID-19 vaccine. 

The latest patent application to surface was applied for by Western Star Management LLC, which appears to be operating in stealth mode. The claims describe reducing circulating levels of pro-inflammatory cytokines tumor necrosis factor-alpha and interleukin 6 (IL-6) in human patients by 25-50% through a full spectrum composition consisting of at least 70% CBD, 3% CBDV, 2% THCV, and 1 % THC. This composition has to be administered for at least 20 days and is claimed to be effective toward Type II diabetes and improving sleep. Recent research has shown that THC could block CBD’s antiviral activity, so it will be interesting to see whether this application can make it to the market. What is certain is that patent investment precedes market activity. 

The future of cannabinoids being used to treat SARS-CoV-2 among other disorders and diseases will rely solely on the results of the clinical tests and trials as GW Pharmaceuticals’ Epidolex experienced. Correlation has been made between people prescribed CBD for epilepsy and reduced COVID-19 infections in this population. Keep up with the cannabinoid for infections scene through the Cannabis Patent Forecast®. Find patent assets covering the aforementioned treatments in the ‘Medications – Respiratory’ and ‘Medications – Immune’ categories.